| Jacoby, Meagan |
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation |
|
|
| Recruiting | 2 | 60 | US | Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis | Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc. | Acute Myeloid Leukemia | 07/26 | 07/26 | | |
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML |
|
|
| Withdrawn | 2 | 48 | NA | Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis | Washington University School of Medicine | Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | 09/26 | 07/28 | | |
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant |
|
|
| Withdrawn | 2 | 35 | NA | Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron | Washington University School of Medicine, Karyopharm Therapeutics Inc | Multiple Myeloma, Myeloma-Associated Amyloidosis | 01/27 | 01/27 | | |
NCT05483010: Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) |
|
|
| Recruiting | 2 | 16 | US | Atorvastatin, Lipitor, Rosuvastatin, Crestor | Washington University School of Medicine | Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes | 05/27 | 05/27 | | |
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas |
|
|
| Active, not recruiting | 2 | 17 | US | Duvelisib, Copiktra, Peripheral blood draw | Washington University School of Medicine, SecuraBio | T-Cell Lymphoma | 07/26 | 07/26 | | |
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance |
|
|
| Active, not recruiting | 2 | 107 | US | Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq | Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology | Acute Myeloid Leukemia | 07/29 | 07/29 | | |
NCT03068819: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant |
|
|
| Recruiting | 1/2 | 110 | US | CIML NK Cell Infusion, CD3+ T Cell Product Infusion | Washington University School of Medicine, National Cancer Institute (NCI), Wugen, Inc., Children's Discovery Institute | Acute Myeloid Leukemia | 10/28 | 10/28 | | |
NCT04742634: Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant |
|
|
| Recruiting | 1/2 | 126 | US | DEC-C, decitabine + cedazuridine, ASTX727, INQOVI®, MyeloSeq-HD | Washington University School of Medicine, Taiho Oncology, Inc. | Myelodysplastic Syndromes | 11/33 | 11/33 | | |
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes |
|
|
| Completed | 1 | 35 | US | vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin | Washington University School of Medicine, Sunesis Pharmaceuticals | Myelodysplastic Syndromes | 12/16 | 04/24 | | |
|
|
NCT03572764: CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome |
|
|
| Active, not recruiting | 1 | 20 | US | CPX-351, Vyxeos™, Daunorubicin and cytarabine, Research skin biopsy, Research blood draw, Research bone marrow aspirate | Washington University School of Medicine, Jazz Pharmaceuticals | Myelodysplastic Syndromes | 11/21 | 03/27 | | |
NCT03770429: AZD6738 for Patients With Progressive MDS or CMML |
|
|
| Recruiting | 1 | 52 | US | AZD6738 | Massachusetts General Hospital, AstraZeneca | Leukemia, Myelodysplastic Syndrome | 05/24 | 05/25 | | |
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients |
|
|
| Terminated | 1 | 4 | US | ApoGraft | Washington University School of Medicine, Cellect Biotechnology | Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant | 12/22 | 12/22 | | |
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Completed | 1 | 55 | US | Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile | Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI) | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease | 04/24 | 05/24 | | |
NCT06538181: Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome |
|
|
| Not yet recruiting | 1 | 15 | US | Pacritinib | Washington University School of Medicine, Swedish Orphan Biovitrum | E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome | 02/27 | 01/29 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
NCT05434598: Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS |
|
|
| Recruiting | N/A | 60 | US | ChromoSeq | Washington University School of Medicine, American Society of Hematology, Edward P. Evans Foundation, National Cancer Institute (NCI) | Whole Genome Sequencing, Myelodysplastic Syndromes | 07/27 | 08/27 | | |
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration |
|
|
| Recruiting | N/A | 165 | US | Peripheral blood draw, Bone marrow aspirate, Buccal swab | Washington University School of Medicine, Notable Labs | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 01/25 | 01/25 | | |
NCT04986657: Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS |
|
|
| Recruiting | N/A | 275 | US | ChromoSeq | Washington University School of Medicine | Whole Genome Sequencing, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 12/27 | 12/27 | | |
NCT02604563: Aging, Geriatric Syndromes and Clonal Hematopoiesis |
|
|
| Recruiting | N/A | 2000 | US | Cognitive Assessment, Activities of Daily Living Questionnaire, Instrumental Activities of Daily Living, subscale of the OARS, Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section, subscale of the OARS, MOS Social Activity Survey, Unintentional Weight Loss, Peripheral Blood Draw, Buccal Swab, Heart Health and Smoking History from BRFSS questionnaire, Gait Speed, Grip Strength, Height and Weight measurements, Blood pressure measurement, Optional bone marrow biopsy, Blood draw for trauma measurements | Washington University School of Medicine, Edward P. Evans Foundation | Geriatrics, Aged, Geriatric Syndromes, Cardiovascular Diseases | 04/30 | 04/30 | | |
| Noland, Jill |
| Recruiting | 2 | 160 | Canada, US | Ferric Citrate, Auryxia, Placebo | University of California, Los Angeles, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Kidney Diseases | 12/25 | 12/25 | | |
